A Jatoi1, B D Daly, G Kramer, J B Mason. 1. Division of Hematology/Oncology, Department of Medicine, New England Medical Center, Tufts University, Boston, MA, USA. jatoi.aminah@mayo.edu
Abstract
BACKGROUND AND OBJECTIVES: This case control study explored the purported inverse relationship between folate status and lung cancer development. METHODS: Folate status of 46 postoperative non-small cell lung cancer (NSCLC) patients was compared to that of 44 non-cancer patients. Cancer patients had completed treatment > 3 months prior and had no evidence of cancer. Ineligibility criteria for all patients included (1) > 2 alcoholic drinks/day (2) ongoing tobacco use, or (3) folate supplementation > 400 microg/day. RESULTS: No differences were found between groups in serum and RBC folate after adjustment for age and use of folate-interfering medications: geometric means (GM) x /geometric standard error (GSE): 7.9 ng/ml x /1.1 vs. 7.8 ng/ml x /1.1, respectively (P = 0.91) for serum folate; 264 ng/ml x /1.1 vs. 263 ng/ml x /1.1, respectively (P = 0.97) for RBC folate. Age- and creatinine-adjusted homocysteine was no different between groups: GM x /GSE: 9.4 micromol/L x /1.0 vs. 8.6 micromol/L x /1.0, respectively (P = 0.17). No difference were seen in folate intake. Frequencies of the homozygous genotype for the MTHFR polymorphism, an enzyme important in folate metabolism and associated with a reduced risk of other cancers, were no different. CONCLUSIONS: This case control study does not support the hypothesis that low folate is an independent risk factor for NSCLC. Copyright 2001 Wiley-Liss, Inc.
BACKGROUND AND OBJECTIVES: This case control study explored the purported inverse relationship between folate status and lung cancer development. METHODS:Folate status of 46 postoperative non-small cell lung cancer (NSCLC) patients was compared to that of 44 non-cancerpatients. Cancerpatients had completed treatment > 3 months prior and had no evidence of cancer. Ineligibility criteria for all patients included (1) > 2 alcoholic drinks/day (2) ongoing tobacco use, or (3) folate supplementation > 400 microg/day. RESULTS: No differences were found between groups in serum and RBC folate after adjustment for age and use of folate-interfering medications: geometric means (GM) x /geometric standard error (GSE): 7.9 ng/ml x /1.1 vs. 7.8 ng/ml x /1.1, respectively (P = 0.91) for serum folate; 264 ng/ml x /1.1 vs. 263 ng/ml x /1.1, respectively (P = 0.97) for RBC folate. Age- and creatinine-adjusted homocysteine was no different between groups: GM x /GSE: 9.4 micromol/L x /1.0 vs. 8.6 micromol/L x /1.0, respectively (P = 0.17). No difference were seen in folate intake. Frequencies of the homozygous genotype for the MTHFR polymorphism, an enzyme important in folate metabolism and associated with a reduced risk of other cancers, were no different. CONCLUSIONS: This case control study does not support the hypothesis that low folate is an independent risk factor for NSCLC. Copyright 2001 Wiley-Liss, Inc.
Authors: Katarzyna Durda; Krzysztof Kąklewski; Satish Gupta; Michał Szydłowski; Piotr Baszuk; Katarzyna Jaworska-Bieniek; Grzegorz Sukiennicki; Katarzyna Kaczmarek; Piotr Waloszczyk; Steven Narod; Jan Lubiński; Anna Jakubowska Journal: PLoS One Date: 2017-05-11 Impact factor: 3.240